187P Phase I/II study of the oral CCR4 antagonist, FLX475, as monotherapy and in combination with pembrolizumab in advanced cancer

Preclinical studies with oral CCR4 antagonists have demonstrated inhibition of suppressive regulatory T cell (Treg) migration into the tumor microenvironment and antitumor efficacy. The FLX475-02 trial is a phase 1/2, open-label, dose-escalation and cohort expansion study to determine the safety and antitumor activity of the oral CCR4 antagonist FLX475 as monotherapy and in combination with pembrolizumab in subjects with several types of advanced cancer.